ImmunityBio, Inc.
IBRXNasdaq
$7.68
↑ +3.1%Jul 17 close · end-of-day
Price
1Y↑ +179.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$7.9B
Enterprise Value
$7.5B
P/E
—
P/S
55.9
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-3.8%
Dividend Yield
—
Revenue (TTM)
$141.0M
Net Income (TTM)
-$854.6M
Free Cash Flow (TTM)
-$298.9M
Gross Margin
—
Operating Margin
-185.4%
Net Margin
-606.2%
ROE
98.2%
ROIC
—
Debt / Equity
-0.0
Net Cash
$380.0M
Return 1Y
+171.4%
Company profile
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers.
- CEO
- Richard Adcock
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 590
- Headquarters
- California
- Website
- immunitybio.com
Management & directors
- Soon-Shiong PatrickSee remarks
- Adcock RichardCEO & President
- Lauer Regan JChief Accounting Officer
- Sachs David C.Chief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
IBRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$44.2M↑ +167.6%
Diluted EPS-$0.62↑ +313.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $605,000.00 | $934,000.00 | $240,000.00 | $622,000.00 | $14.7M | $113.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$220.9M | -$330.3M | -$351.3M | -$362.3M | -$344.2M | -$256.0M |
| Net income | -$221.9M | -$349.8M | -$417.3M | -$583.9M | -$413.6M | -$351.5M |
| Diluted EPS | -$0.59 | -$0.89 | -$1.04 | -$1.15 | -$0.62 | -$0.38 |
| Operating cash flow | -$171.7M | -$274.4M | -$337.5M | -$366.8M | -$391.2M | -$304.9M |
| Free cash flow | -$173.4M | -$308.0M | -$415.7M | -$397.3M | -$398.1M | -$308.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -36509.1% | -35361.9% | -146374.2% | -58239.5% | -2334.2% | -226.0% |
| Net margin | -36669.6% | -37451.8% | -173875.0% | -93874.6% | -2805.0% | -310.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $6.1M | $7.6M | $16.5M | $26.4M | $32.1M | $38.3M | $44.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$99.3M | -$80.3M | -$69.4M | -$64.4M | -$71.3M | -$55.6M | -$64.7M | -$69.8M |
| Net income | -$134.6M | -$85.7M | -$59.2M | -$129.6M | -$92.6M | -$67.3M | -$62.0M | -$632.8M |
| Diluted EPS | -$0.20 | -$0.14 | -$0.08 | -$0.15 | -$0.10 | -$0.07 | -$0.06 | -$0.62 |
| Operating cash flow | -$100.3M | -$98.8M | -$85.1M | -$85.9M | -$79.7M | -$68.9M | -$70.4M | -$75.4M |
| Free cash flow | -$101.1M | -$101.6M | -$87.3M | -$87.0M | -$80.8M | -$69.6M | -$71.3M | -$77.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -9487.4% | -1314.3% | -919.0% | -390.1% | -269.8% | -173.5% | -169.0% | -157.9% |
| Net margin | -12852.3% | -1404.0% | -783.9% | -784.9% | -350.3% | -209.8% | -162.1% | -1431.4% |
Company news
Jul 16, 2026
Jul 10, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | Cohen Cheryl | Sale | 131,210 | $9.50 | $1.2M | filing |
| 2026-07-02 | Cohen Cheryl | Option exercise | 55,979 | $2.98 | $166,817.42 | filing |
| 2026-07-01 | Selecky Christobel | Sale | 159,478 | $9.02 | $1.4M | filing |
| 2026-07-01 | Selecky Christobel | Option exercise | 124,414 | $2.99 | $371,997.86 | filing |
| 2026-07-01 | Selecky Christobel | Option exercise | 35,064 | $2.98 | $104,490.72 | filing |
| 2026-06-30 | Selecky Christobel | Sale | 1,000 | $9.00 | $9,000.00 | filing |
| 2026-06-30 | Selecky Christobel | Option exercise | 700 | $2.98 | $2,086.00 | filing |
| 2026-06-30 | Selecky Christobel | Option exercise | 300 | $2.99 | $897.00 | filing |
| 2026-06-29 | Selecky Christobel | Sale | 95,722 | $9.01 | $862,215.92 | filing |
| 2026-06-29 | Selecky Christobel | Option exercise | 33,549 | $2.99 | $100,311.51 | filing |
| 2026-06-29 | Selecky Christobel | Option exercise | 32,173 | $2.98 | $95,875.54 | filing |
| 2026-06-29 | Selecky Christobel | Option exercise | 30,000 | $2.84 | $85,200.00 | filing |
| 2026-06-24 | Simon Barry J. | Sale | 25,000 | $7.88 | $196,907.50 | filing |
| 2026-06-04 | Simon Barry J. | Sale | 23,033 | $7.18 | $165,305.54 | filing |
| 2026-03-31 | SOON-SHIONG PATRICK· See remarks | C | 4,606,596 | $5.43 | $25.0M | filing |
| 2026-02-24 | Simon Barry J. | Sale | 75,000 | $12.01 | $900,787.50 | filing |
| 2026-02-23 | Simon Barry J. | Sale | 165,000 | $10.25 | $1.7M | filing |
| 2026-02-23 | Selecky Christobel | Sale | 25,000 | $10.00 | $250,000.00 | filing |
| 2026-02-23 | Selecky Christobel | Option exercise | 25,000 | $2.98 | $74,500.00 | filing |
| 2026-02-22 | Adcock Richard· CEO & President | Tax withholding | 77,560 | $8.70 | $674,772.00 | filing |
| 2026-02-22 | SOON-SHIONG PATRICK· See remarks | Tax withholding | 58,170 | $8.70 | $506,079.00 | filing |
| 2026-02-22 | Sachs David C.· Chief Financial Officer | Tax withholding | 20,682 | $8.70 | $179,933.40 | filing |
| 2026-02-22 | Simon Barry J. | Tax withholding | 6,026 | $8.70 | $52,426.20 | filing |
| 2026-02-22 | LAUER REGAN J· Chief Accounting Officer | Tax withholding | 1,673 | $8.70 | $14,555.10 | filing |
| 2026-02-22 | Sachs David C.· Chief Financial Officer | Option exercise | 40,650 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.